Anticancer drug dosing recommendations in kidney dysfunction are often empirical, based on non-standardised creatinine assays calculated via the Cockcroft-Gault equation, and lack applicability to globally accepted kidney dysfunction classifications. The ADDIKD guideline aims to provide a consensus-based standardised approach to the measurement of kidney function in cancer patients and its application to anticancer drug dosing. An expert international multidisciplinary guideline working group was established to develop drug dosing recommendations that were based on internationally accepted approaches in determining kidney function and classifying levels of dysfunction. This standardised approach reduces complexity of kidney function estimation, promotes uniformity of measurement and informs dosing calculations, to encourage consistency and safer delivery of anticancer treatment.